Sirolimus, a potent inhibitor of B- and T-cell activation. is a commonly used immunosuppressant after renal transplantation. Withdrawal of sirolimus from the immunosuppression regimen may reduce B-cell surveillance. We present a case of rapidly progressive central nervous system (CNS) polymorphic Epstein-Barr virus (EBV)-related post-transplant lymphoproliferative disorder following the withdrawal of sirolimus.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7196/samj.5500 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term effects of sirolimus treatment for slow-flow vascular malformations: Real-world evidence from the French observational multicentre SIROLO study.
J Eur Acad Dermatol Venereol
November 2024
Unit of Pediatric Dermatology, Department of Dermatology, University Hospital Center (CHRU) of Tours, Tours, France.
Rationale: Sirolimus is a treatment for slow-flow vascular malformations (SFVMs). However, the long-term management remains challenging.
Objectives: The SIROLO study assessed the long-term effects and real-life management of oral sirolimus for SFVMs by investigating data from 15 French tertiary centres for vascular anomalies.
The Effect of Everolimus Versus Calcineurin Inhibitors on Quality of Life 10-12 Years After Heart Transplantation: The Results of a Randomized Controlled Trial (SCHEDULE Trial).
Clin Transplant
November 2024
Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Background: Calcineurin inhibitors (CNIs) are associated with long-term complications after heart transplantation (HTx). Everolimus (EVR)-based immunosuppression allows for CNI withdrawal. We used data from The Scandinavian heart transplant everolimus de novo study with early CNI avoidance (SCHEDULE) trial to assess whether health-related quality of life (HRQoL) differed between patients on long-term treatment with EVR versus a CNI-based regimen.
View Article and Find Full Text PDFLate-onset tacrolimus-induced encephalopathy in lung transplant recipient: Case report.
Heliyon
November 2024
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Organ transplantation, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, PR China.
Article Synopsis
- * A case study of a 61-year-old woman showed confusion and muscle stiffness 29 months post-lung transplant, revealing a diagnosis of tacrolimus-induced encephalopathy despite normal drug levels in her blood.
- * After switching her treatment from tacrolimus to cyclosporine, her neurological symptoms improved, indicating that tacrolimus was the cause of her condition, even when drug levels were considered safe.
Gastric Bleeding in Stem Cell Transplantation: A Focus on Gastric Vascular Ectasia Under Post-Transplant Cyclophosphamide, Sirolimus, and Mycophenolate Mofetil Prophylaxis.
Transplant Cell Ther
January 2025
Hospital Universitari i Politècnic La Fe, Valencia, Spain; Instituto de Investigación Sanitaria La Fe (IIS La Fe), Valencia, Spain; Departamento de Medicina, Universidad de Valencia, Valencia, Spain; CIBERONC, Instituto Carlos III, Madrid, Spain.
Gastrointestinal bleeding (GIB) is a serious complication following allogeneic hematopoietic stem cell transplantation (HSCT), with limited data on its incidence and characteristics, particularly for upper gastrointestinal bleeding (UGIB) of gastric origin. We aimed to evaluate the incidence, clinical, endoscopic, and histopathologic features, and outcomes of UGIB, with a focus on gastric vascular ectasias (GVEs) in patients undergoing HSCT with graft-versus-host disease (GVHD) prophylaxis using post-transplant cyclophosphamide (PTCY), sirolimus or calcineurin inhibitors, and mycophenolate mofetil. This retrospective, single-center study included all adult patients who underwent allogeneic HSCT at a single institution between January 2017 and December 2023.
View Article and Find Full Text PDFLong-term follow-up of the randomized, prospective Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE) trial.
J Heart Lung Transplant
December 2024
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Article Synopsis
- Early substitution of calcineurin inhibitors (CNI) with everolimus in heart transplant patients showed improved long-term kidney function compared to standard CNI therapy.
- In a study involving 115 heart transplant recipients, those on everolimus maintained significantly better kidney health over 10-12 years, with an estimated glomerular filtration rate (eGFR) of 82.7 ml/min/1.73 m² versus 61.0 ml/min/1.73 m² for the standard CNI group.
- Despite the differences in kidney function, survival rates and overall graft performance were similar between both treatment groups, indicating that both approaches are viable long-term.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!